Man Group plc Acquires 4,384 Shares of Becton, Dickinson and Company $BDX

Man Group plc raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 30.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 18,549 shares of the medical instruments supplier’s stock after acquiring an additional 4,384 shares during the quarter. Man Group plc’s holdings in Becton, Dickinson and Company were worth $2,807,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BDX. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the third quarter valued at $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth about $29,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the last quarter. Finally, Tucker Asset Management LLC acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BDX shares. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a report on Monday, July 6th. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Finally, The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Trading Down 0.7%

Shares of Becton, Dickinson and Company stock opened at $188.13 on Tuesday. The stock has a market capitalization of $51.84 billion, a PE ratio of 56.67, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The stock has a 50 day moving average price of $167.10 and a two-hundred day moving average price of $160.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 9,105 shares of company stock valued at $1,590,208. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.